Protara Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $199.2M | $168.6M |
| FY2021 | — | $161.9M | $35.7M |
| FY2022 | — | $102.1M | $24.1M |
| FY2023 | — | $68.3M | $39.6M |
| FY2024 | — | $167.1M | $162.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $199.2M | $168.6M |
| FY2021 | — | $161.9M | $35.7M |
| FY2022 | — | $102.1M | $24.1M |
| FY2023 | — | $68.3M | $39.6M |
| FY2024 | — | $167.1M | $162.8M |